Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
Pfizer said on August 8 that it has obtained Japanese regulatory approval for an updated monovalent version of its COVID-19 vaccine adapted to the currently circulating JN.1 Omicron subvariant. It is allowed for use in individuals six months of age…
To read the full story
Related Article
- Pfizer’s JN.1 COVID Jabs for Children, Infants Now Available in Japan
November 18, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Moderna’s JN.1-Tailored COVID Vaccine Approved in Japan
August 26, 2024
- Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…